Loading
RVU120 is a small-molecule inhibitor from Ryvu Therapeutics SA, in registered phase 2 trials for acute myeloid leukaemia.
RVU120 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Ryvu Therapeutics SA, in acute myeloid leukaemia. Described in the registry record as a selective inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a selective inhibitor; the trial entries below carry the sponsor's wording.
1.RVU120 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"RVU120" OR ABSTRACT:"RVU120" OR TITLE:"SEL120" OR ABSTRACT:"SEL120") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RVU120, not a curated reading list.
Shares Acute myeloid leukaemia and the tags pipeline, registry-only.
Shares Acute myeloid leukaemia and the tags pipeline, registry-only.
Shares Ryvu Therapeutics and the tag pipeline.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.